Can Globus Medical Stock Rally 30% After This Dip?
For questions about this article or underlying research, email help@trefis.com.
Shares of Globus Medical (GMED) have fallen 19.1% since November 4, 2026. The slide began on November 5, when the company lowered its 2026 revenue forecast while reporting its third quarter. A 30% rally from here depends on whether new spine products such as SCRIPT, which management now counts on for 2027, start adding to sales. Following earlier drops like this one, the stock’s best price within a year sat a median 39.3% above the dip-date price. But where did those earlier drops leave a buyer a year later?

Globus Medical Stock Rose A Year After Most Dips
Since August 2012, Globus Medical stock has recorded 11 drops of more than 20% in 30 trading days, with a full year passing since each decline. Ten of those drops left the stock higher twelve months later, and the median change across all 11 was a 37% gain.
That gain involved a further fall and a long wait. In the year after a typical drop, the stock’s lowest close sat a median 10.2% below the dip-date price. The best price surfaced later, arriving a median 340 days, or about 11 months, after the initial dip. Following the March 2025 drop, the stock fell as far as 29.4% below its dip-date price before ending the year 20% higher.
| Time after a past dip | Past dips with that much time after them | Median GMED price change |
|---|---|---|
| 21 trading days | 11 | 1.0% |
| 63 trading days | 11 | 9.0% |
| 126 trading days | 11 | 14.0% |
| 252 trading days | 11 | 37.0% |
| Dip date | Fall to dip date (GMED / SPY) | 1 year later | Best in that year (days to it) | Worst in that year |
|---|---|---|---|---|
| 2025-06-23 | -20.2% / 7.0% | 46.0% | 67.5% (301 days) | -10.2% |
| 2025-05-09 | -24.2% / 0% | 37.0% | 73.5% (346 days) | -7.0% |
| 2025-03-11 | -20.1% / -7.0% | 20.0% | 31.6% (352 days) | -29.4% |
| 2023-02-13 | -20.3% / 8.0% | -11.0% | 4.9% (155 days) | -26.3% |
| 2022-06-16 | -22.2% / -15.0% | 8.0% | 50.0% (232 days) | -2.4% |
| 2020-03-09 | -25.6% / -17.0% | 57.0% | 72.9% (340 days) | -10.5% |
| 2018-12-19 | -20.2% / -8.0% | 37.0% | 36.6% (365 days) | -12.6% |
| 2016-02-11 | -20.6% / -12.0% | 19.0% | 22.0% (337 days) | -7.8% |
| 2015-09-29 | -22.5% / -10.0% | 9.0% | 34.6% (92 days) | -1.5% |
| 2014-08-06 | -23.4% / -1.0% | 45.0% | 51.6% (359 days) | -2.0% |
| 2012-11-13 | -24.4% / -4.0% | 37.0% | 39.3% (352 days) | -23.9% |
| Median of 11 complete years | – | 37.0% | 39.3% (340 days) | -10.2% |
Is Globus Medical’s Sales Growth Coming Back?
Not yet: in the third quarter of fiscal 2026, Globus Medical’s revenue was $764 million, 0.7% lower than a year earlier. Management cut its 2026 revenue forecast to $3.09 billion, from a range of $3.18 billion to $3.22 billion. It said SCRIPT, its new line of patient-specific spine implants, and the other delayed launches will not add meaningful growth until 2027. U.S. Spine grew 2% in the quarter, while revenue from Nevro, the pain-treatment company Globus Medical acquired, fell 25.7%.
While sales have stalled, the business has grown more profitable. Over the four quarters to September 2026, its operating margin was 22.8%, up from 15.6% a year earlier. Cash from operations reached $926 million, against $715 million a year earlier. Buyers now pay 17.0 times trailing earnings for the stock, against 21.9 for the S&P 500.
What Could A Globus Medical Buyer Lose?
The typical one-year gain after past drops hides a wide spread. Twelve months after a drop, the stock’s results ran from an 11% loss to a 57% gain. The loss followed the February 2023 drop, after which the stock never rose more than 4.9% above its dip-date price within a year.
Even before any further slip in the spine launches, a buyer is holding a company that expects its fourth-quarter sales to fall. Management said its forecast implies a mid-single-digit sales decline in the fourth quarter, and it is not yet giving a forecast for 2027.
Although Globus Medical’s past drops have mostly ended higher a year on, the sales recovery from its new spine products has not started. When Globus Medical next reports, expected in February 2027, U.S. Spine’s sales growth is the measure to watch.
That report remains months away. If you would rather wait for it before buying, you can keep the money you set aside earning something in the meantime.
Waiting To Buy Globus Medical? Why Let Your Cash Sit Idle?
The right price can take months. Meanwhile, the Trefis Income Solution pays a dividend yield about 3x the S&P 500’s, from 50 stocks with at least 10 straight years of dividends. Why not choose a better approach?
Spot an error or want more like this? Tell us in 10 seconds.